Last $4.24 USD
Change Today +0.13 / 3.16%
Volume 850.7K
ARRY On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Open
$4.16
Previous Close
$4.11
Day High
$4.28
Day Low
$4.12
52 Week High
08/2/13 - $7.10
52 Week Low
04/15/14 - $3.39
Market Cap
534.2M
Average Volume 10 Days
2.4M
EPS TTM
$-0.54
Shares Outstanding
126.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company’s partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs; and Biogen Idec for the discovery and development of inhibitors to treat autoimmune disorders. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

265 Employees
Last Reported Date: 08/12/13
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $528.2K
Co-Founder, Chief Operating Officer and Vice ...
Total Annual Compensation: $384.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $348.9K
Vice President, General Counsel and Secretary
Total Annual Compensation: $357.5K
Chief Medical Officer
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2013.

array biopharma inc (ARRY) Key Developments

Array BioPharma, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-18-2014 08:20 AM

Array BioPharma, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-18-2014 08:20 AM. Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

Array BioPharma, Inc. Announces a Collaboration Agreement with Biogen Idec Inc

Array BioPharma announced a collaboration agreement with Biogen Idec for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders. The collaboration target and lead inhibitors were discovered through Array's proprietary Kinase-Directed Phenotypic Screening Platform. This technology relies on Array's deep experience in kinase inhibitor chemistry and phenotypic screening which can be applied to any therapeutic area where a desired cellular phenotype can be envisioned. Under the terms of the agreement, Biogen and Array will collaborate on the discovery of the novel kinase inhibitors. Biogen will be responsible for all aspects of clinical development and commercialization.

Array BioPharma, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:00 PM

Array BioPharma, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $4.24 USD +0.13

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CrystalGenomics Inc 16,300 KRW +150.00
CTI BioPharma Corp $2.65 USD +0.05
Progenics Pharmaceuticals Inc $5.03 USD 0.00
Spectrum Pharmaceuticals Inc $7.20 USD +0.25
Wyeth Ltd 929.30 INR -10.50
View Industry Companies
 

Industry Analysis

ARRY

Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit www.arraybiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.